Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on UDG HEALTHCARE PLC. We currently have 22 research reports from 2 professional analysts.
|12Apr17 07:00||RNS||Appointment announcement|
|03Apr17 07:00||RNS||Director Declaration|
|31Mar17 14:39||RNS||Total Voting Rights|
|29Mar17 12:16||RNS||Holding(s) in Company|
|28Mar17 12:40||RNS||Director/PDMR Shareholding|
|21Mar17 15:03||RNS||Holding(s) in Company|
|06Mar17 11:46||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
UDG HEALTHCARE PLC
UDG HEALTHCARE PLC
N+1 Singer - T2 Trend spotting - Strategy update
31 Mar 17
In our second edition of “Trend spotting” we note how in the last three weeks the defensive rotation trend has gathered pace and further evidence has emerged of the “relative fading” in the UK economy. However we now see early signs of the “risk on” trend starting to reassert itself in equity markets and we look at small cap laggards plus European exposure as ways to play this.
N+1 Singer - Morning Song 31-03-2017
31 Mar 17
Cathay International Holdings Limited (CTI LN) FY results: Solid trading at Lansen; negative impact from FX and Haizi | CVS Group (CVSG LN) Excellent interims. Reappraising mid-term earnings potential | Dechra Pharmaceuticals (DPH LN) IP licensing agreement and minority investment | eg solutions (EGS LN) Significant contract win | Entertainment One Ltd (ETO LN) Trading update for YE Mar’17 | Harwood Wealth (HW LN) £10m new equity to maintain impressive pace | iomart Group (IOM LN) Year end trading update | Mobile Streams (MOS LN) The start…| Oxford Pharmascience Group (OXP LN) FDA feedback: clinical outcomes data required for GI safety claim | Speedy Hire (SDY LN) In line trading update | T2 Trend spotting Strategy update | Imperial Innovations Group (IVO LN) H1 results: solid portfolio progress and net fair value gain
N+1 Singer - UDG Healthcare - Strong Q1 update
07 Feb 17
A strong Q1 update reassures that UDG is capitalising on the twin investment theses of structural growth in the pharma outsourcing market and mix driven margin enhancement. The company is guiding to +13-16% EPS growth at CER, driven by good organic growth and recent acquisitions. The health net cash position also means UDG retains significant firepower for further deals, which should lead to further upgrade momentum in due course. We are reviewing our forecasts for the change in reporting currency and will reissue these shortly.
N+1 Singer - UDG Healthcare - First acquisition heralds start of an upgrade cycle
25 Oct 16
UDG’s first material acquisition since the disposal of the Supply Chain division in April gives some flavour of the direction ahead. It is paying just over 8x EBITDA for a fast growing and high margin business, which will bring a unique service offering into the Ashfield mix. Although FX and opex related to the Future Fit programme temper our EPS upgrades to 3%, we expect further accretive deals to follow. We increase our TP to 746p and reiterate our Buy recommendation.
Updating estimates on H116, FX moves
21 Jul 16
We are updating our forecasts for UDG on the back of solid H116 results, the completion of the sale of the drug distribution business and recent pronounced currency moves. While providing a sufficient cash cushion in the current volatile market conditions, the divestment will allow increased flexibility for the company to deliver on its already successful track record of acquisitions. We raise our DCF valuation from £5.21 to £6.45/share.
20 Apr 17
Although the last two months have seen a broadly neutral performance from the UK healthcare sector compared to a significantly more volatile 6 months prior, we continue to expect macro-events and increased geo-political risk to result in an overall neutral performance from the sector over the next period. However, company specific news is likely to drive a strong outperformance from selected mid-market companies. We retain our neutral sector stance whilst highlighting those we expect to outperform.
Positive top-line results in first iclaprim phase III clinical trial (REVIVE-1)
18 Apr 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), a late clinical stage antibiotic development company, announced positive results this morning in the first of its two iclaprim phase III clinical trials, REVIVE-1, comparing iclaprim to vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Iclaprim, a next-generation antibiotic targeting an underutilised mechanism of action which causes rapid killing of bacteria, is being developed for the treatment of serious and life threatening bacterial infections. On the key primary endpoint in the study, early clinical response at 48-72 hours after drug treatment began, 80.9% of patients on iclaprim achieved a positive response compared to 81.0% of patients on vancomycin, well within the 10% non-inferiority margin required by the FDA. Iclaprim was also shown to be safe and well-tolerated compared to vancomycin. With these positive results from REVIVE-1 we have increased the probability of success for the iclaprim development program from 65% to 75% raising our risk-adjusted NPV for Motif Bio to almost £240m or 122p per share (previously £210m and 107p per share).
N+1 Singer - Small-cap quantitative research - Growth style screen revamp and 10 focus stocks
06 Apr 17
We have reviewed the performance of our consistent growth screen since the previous refresh on 27 September 2016 and revamped the selection parameters to focus more on forecast sales and EPS growth going forward. In the period under review the consistent growth style screen outperformed the small-cap benchmark by c. 6% and underperformed the microcap index by a similar amount. Interestingly, although growth doesn’t always seem to be defensive as might be expected, however it appears right to buy growth on dips caused by or coincident with wider market volatility. In the new forecast growth screen we take a close look at 10 focus stocks. We will monitor performance and refresh it in three to four months time.
N+1 Singer - Sinclair Pharma - EBITDA upgrade for 2017, but lower TP due to warranty claim and costs
19 Apr 17
We have updated product-level forecasts and included the £10m SVB debt facility and £5m warranty claim settlement with Alliance Pharma in our forecasts. The 6.3% upgrade to our FY2017 sales estimate (from £46.0m to £48.9m) brings expected EBITDA profitability forward by one year (to FY2017 from FY2018). We remain positive on the ongoing rollout of Silhouette Instalift® in particular and retain our Buy recommendation. However, higher expected sales & marketing costs and the warranty claim weigh on our valuation: we downgrade our target price from 42p to 37p.
Positive REVIVE-1 Phase III study data
18 Apr 17
Motif Bio (MTFB) has announced positive top-line results from REVIVE-1, its global Phase III study comparing iclaprim to vancomycin in patients with acute bacterial skin and skin structure infections (ABSSSI). Iclaprim achieved the primary endpoint of non inferiority when compared to vancomycin, in both the early time point and test of cure endpoint. Iclaprim offers clinical advantages over existing hospital antibiotics that include the avoidance of renal toxicity, fixed dosage regimen and early response indications. With data from REVIVE-2 due out in H2 2017 we maintain our 125p price target and Buy recommendation.